StockNews.AI
ICCM
StockNews.AI
13 days

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

1. IceCure Medical to announce financial results on August 13, 2025. 2. The company specializes in minimally-invasive cryoablation for tumor treatment. 3. Conference call will provide insights into corporate developments. 4. Forward-looking statements caution about potential risks and uncertainties. 5. Focus areas include breast, kidney, bone, and lung cancer treatments.

6m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial report could indicate operational growth and investor interest, similar to past earnings that positively influenced stock prices.

How important is it?

Upcoming earnings announcement could significantly inform market perceptions and driving demand for ICCM.

Why Short Term?

The financial report is imminent, likely affecting stock price swiftly, akin to responses seen in quarterly earnings announcements.

Related Companies

ICECMDGLCRMD
, /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced  it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2025 before the Nasdaq Stock Market opens on Wednesday, August 13, 2025. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, August 13, 2025, at 11:00 am EDTUS: 1-888-407-2553Israel/International: +972-3-918-0696A live webcast will be available at: https://www.veidan-conferenceing.com/icecureA recording of the webcast will be available at: ir.icecure-medical.com/ About IceCure MedicalIceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: its expected announcement of financial and operational results as of and for the six months ended June 30, 2025 and hosting a conference call related to such results . Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. IR Contact: Email: [email protected] Michael Polyviou Phone: 732-232-6914 Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg SOURCE IceCure Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News